Nisylat tablet p/pl/o 600 mg N20 (DrRedis)

Pharmaceutical action: Amtolmetin guacil is an NSAID, a non-selective cyclooxygenase (COX) inhibitor. Amtolmetin guacil is a precursor to tolmetin. It has an anti-inflammatory, analgesic, antipyretic, desensitizing effect, and has a gastroprotective effect. Suppresses pro-inflammatory factors, reduces platelet aggregation; inhibits COX-1 and COX-2, disrupts the metabolism of arachidonic acid, reduces the formation of prostaglandins (including at the site of inflammation), suppresses the exudative and proliferative phases of inflammation. Reduces capillary permeability; stabilizes lysosomal membranes; inhibits the synthesis or inactivates inflammatory mediators (prostaglandins, histamine, bradykinins, cytokines, complement factors). Blocks the interaction of bradykinin with tissue receptors, restores impaired microcirculation and reduces pain sensitivity at the site of inflammation. Affects the thalamic centers of pain sensitivity; reduces the concentration of biogenic amines with algogenic properties; increases the pain sensitivity threshold of the receptor apparatus. Eliminates or reduces the intensity of pain, reduces morning stiffness and swelling, increases the range of motion in the affected joints after 4 days of treatment. The protective effect of amtolmetin guacil on the gastric mucosa is realized by stimulating capsaicin receptors (also called vanilloid receptors) present in the walls of the gastrointestinal tract. Due to the presence of a vanillin group in amtolmetin guacil, it can stimulate capsaicin receptors, which in turn causes the release of calcitonin gene-encoded peptide (CAGP) and a subsequent increase in nitric oxide (NO) production. Both of these actions counterbalance the negative effect caused by the decrease in prostaglandins due to COX inhibition. Amtolmetin guacil was well tolerated by patients with long-term use (for 6 months). Pharmacokinetics: Absorption of amtolmetin guacil after oral administration is rapid and complete. Basically, the drug is concentrated in the walls of the stomach and intestines, where its very high concentration is maintained for 2 hours after administration. The time to reach Cmax after oral administration is 20-60 minutes. Plasma protein binding - 99%. After absorption, amtolmetin guacil is immediately hydrolyzed by plasma esterases to form three metabolites: MED5, tolmetin and guacol, which are transformed to the active metabolite tolmetin, which penetrates the tissues, exerting a pharmacological effect. The main metabolic pathway of tolmetin is the oxidation of the methyl group at the benzene ring into a carboxyl group. T1/2 in adults is about 5 hours. Within 24 hours, the drug is almost completely eliminated from the body in the form of glucuronides (with urine - 80%, with bile - 20%).

Buy Nisylat film-coated tablets 600 mg No. 20 in pharmacies

Instructions for use Nizilat Dosage forms tablets 600 mg Synonyms There are no synonyms. Group Nonsteroidal anti-inflammatory drugs International nonproprietary name Amtolmetin guacil Manufacturers Dr. Reddis Laboratories Ltd. (India) Pharmacological action Amtolmetin guacil is a NSAID, a non-selective cyclooxygenase (COX) inhibitor. Amtolmetin guacil is a precursor to tolmetin. It has an anti-inflammatory, analgesic, antipyretic, desensitizing effect, and has a gastroprotective effect. Suppresses pro-inflammatory factors, reduces platelet aggregation; inhibits COX-1 and COX-2, disrupts the metabolism of arachidonic acid, reduces the formation of prostaglandins (including at the site of inflammation), suppresses the exudative and proliferative phases of inflammation. Reduces capillary permeability; stabilizes lysosomal membranes; inhibits the synthesis or inactivates inflammatory mediators (prostaglandins, histamine, bradykinins, cytokines, complement factors). Blocks the interaction of bradykinin with tissue receptors, restores impaired microcirculation and reduces pain sensitivity at the site of inflammation. Affects the thalamic centers of pain sensitivity; reduces the concentration of biogenic amines with algogenic properties; increases the pain sensitivity threshold of the receptor apparatus. Eliminates or reduces the intensity of pain, reduces morning stiffness and swelling, increases the range of motion in the affected joints after 4 days of treatment.

The protective effect of amtolmetin guacil on the gastric mucosa is realized by stimulating capsaicin receptors (also called vanilloid receptors) present in the walls of the gastrointestinal tract. Due to the presence of a vanillin group in amtolmetin guacil, it can stimulate capsaicin receptors, which in turn causes the release of calcitonin gene-encoded peptide (CAGP) and a subsequent increase in nitric oxide (NO) production. Both of these actions counterbalance the negative effect caused by the decrease in prostaglandins due to COX inhibition. Amtolmetin guacil was well tolerated by patients with long-term use (for 6 months).

PHARMACOKINETICS Absorption and distribution

Absorption of amtolmetin guacil after oral administration is rapid and complete. Basically, the drug is concentrated in the walls of the stomach and intestines, where its very high concentration is maintained for 2 hours after administration. The time to reach Cmax after oral administration is 20-60 minutes.

Plasma protein binding - 99%.

Metabolism

After absorption, amtolmetin guacil is immediately hydrolyzed by plasma esterases to form three metabolites: MED5, tolmetin and guacol, which are transformed to the active metabolite tolmetin, which penetrates the tissues, exerting a pharmacological effect. The main metabolic pathway of tolmetin is the oxidation of the methyl group at the benzene ring into a carboxyl group.

Removal

T1/2 in adults is about 5 hours. Within 24 hours, the drug is almost completely eliminated from the body in the form of glucuronides (with urine - 80%, with bile - 20%).

Indications rheumatoid arthritis; osteoarthritis; ankylosing spondylitis; articular syndrome during exacerbation of gout; bursitis; Tenosynovitis. Pain syndrome (mild to moderate intensity):

arthralgia; myalgia; neuralgia; migraine; toothache and headache; algodismenorrhea; pain from injuries, burns. Intended for symptomatic therapy, reducing pain and inflammation at the time of use; does not affect the progression of the disease.

Contraindications: hypersensitivity to amtolmetin, tolmetin; complete or incomplete combination of bronchial asthma, recurrent nasal polyposis or paranasal sinuses and intolerance to acetylsalicylic acid and other NSAIDs (including a history); erosive and ulcerative changes in the mucous membrane of the stomach and duodenum; active gastrointestinal bleeding; cerebrovascular or other bleeding; inflammatory bowel diseases (Crohn's disease, ulcerative colitis) in the acute phase; hemophilia and other bleeding disorders; decompensated heart failure; liver failure or active liver disease; severe renal failure (creatinine Cl less than 30 ml/min), progressive kidney disease, confirmed hyperkalemia; period after coronary artery bypass surgery; arterial hypertension; congenital lactase deficiency, lactose intolerance, glucose-galactose malabsorption; deficiency of glucose-6-phosphate dehydrogenase; pregnancy; lactation period; children under 18 years of age. With caution: hyperbilirubinemia; chronic heart failure; cardiac ischemia; cerebrovascular diseases; dyslipidemia/hyperlipidemia; diabetes; peripheral arterial disease; smoking; chronic renal failure (Clcreatinine 30-60 ml/min); history of ulcerative lesions of the gastrointestinal tract; presence of H. pylori infection; long-term use of NSAIDs; alcoholism; severe somatic diseases; elderly age; simultaneous use of oral corticosteroids (including prednisolone), anticoagulants (including warfarin), antiplatelet agents (including acetylsalicylic acid, clopidogrel), SSRIs (including citalopram, fluoxetine, paroxetine, sertraline ).

Special instructions During treatment with Naysilat, monitoring of the peripheral blood picture and the functional state of the liver and kidneys is necessary. Treatment should be stopped 48 hours before determination of 17-ketosteroids. During treatment, you should refrain from engaging in potentially hazardous activities that require increased attention and speed of mental and motor reactions.

Composition Each film-coated tablet contains: Active substance: amtolmetin guacil 600 mg; Excipients: lactose monohydrate 40.1 mg, hypromellose (15 cps) 6.0 mg, lactose monohydrate (Flowlac 100) 120.3 mg, colloidal silicon dioxide 1.6 mg, sodium carboxymethyl starch (type-A) 24.0 mg , magnesium stearate 8.0 mg; Film coating: hypromellose (5 pps) 12.5 mg, titanium dioxide 6.25 mg, macrogol-400 1.25 mg.

Method of administration and dosage The recommended dose of Naysylat is 600 mg twice a day. Depending on the degree of control of the symptoms of the disease, the maintenance dose may be reduced to 600 mg once daily. The maximum daily dose is 1800 mg. To maintain the gastroprotective effect of the drug, Naysylat should be taken on an empty stomach.

Side effects From the digestive system: often - nausea; uncommon - dyspepsia, discomfort in the stomach and intestines, bloating; rarely - abdominal pain, diarrhea, vomiting, constipation, gastritis, very rarely - peptic ulcer, liver dysfunction.

From the urinary system: increased urea nitrogen levels in the blood, urinary tract infections.

From the senses: rarely - tinnitus, visual impairment.

From the respiratory system: rarely - bronchospasm, shortness of breath, rhinitis, laryngeal edema.

From the side of the central nervous system: often - dizziness, headache, drowsiness; rarely - depression.

From the cardiovascular system: often - increased blood pressure.

From the hematopoietic organs: rarely - anemia, thrombocytopenia, agranulocytosis, leukopenia.

From the skin: uncommon - skin rash (including maculopapular rash), purpura; rarely - exfoliative dermatitis (fever with or without chills, redness, thickening or peeling of the skin, swelling and/or tenderness of the tonsils), urticaria, Stevens-Johnson syndrome, Lyell's syndrome.

Allergic reactions: rarely - anaphylaxis or anaphylactoid reactions (change in facial skin color, skin rash, urticaria, itching of the skin, tachypnea or dyspnea, swelling of the eyelids, periorbital edema, shortness of breath, difficulty breathing, heaviness in the chest, wheezing).

Other: often - weakness; uncommon - swelling (face, legs, ankles, fingers, feet, weight gain); rarely - increased sweating, fever, lymphadenopathy; very rarely - swelling of the tongue.

Drug interactions Inducers of microsomal oxidation in the liver (phenytoin, ethanol, barbiturates, rifampicin, phenylbutazone, tricyclic antidepressants) increase the production of hydroxylated active metabolites. Reduces the effectiveness of uricosuric, antihypertensive drugs and diuretics. Enhances the hypoglycemic effect of sulfonylurea derivatives, the effect of anticoagulants, antiplatelet agents, fibrinolytics, side effects of estrogens, glucocorticosteroids and mineralcorticoids. Antacids and cholestyramine reduce absorption. Increases the concentration of lithium and methotrexate in the blood. In some patients with impaired renal function, co-administration of NSAIDs and angiotensin-converting enzyme (ACE) inhibitors may result in further deterioration of renal function. Myelotoxic drugs increase the manifestations of hematotoxicity of the drug. Check the interaction of other drugs with Naisylat

Overdose Symptoms: abdominal pain, nausea, vomiting, erosive and ulcerative lesions of the gastrointestinal tract, impaired renal function, metabolic acidosis.

Treatment: gastric lavage, administration of adsorbents (activated carbon) and symptomatic therapy (maintaining vital body functions). There is no specific antidote.

Storage conditions: In a dry place, protected from light, at a temperature not exceeding 25 °C.

Shelf life: 2 years.

Contraindications

Allergy to tolmetin, amtolmetin.
The presence of bronchial asthma , allergy to Aspirin or recurrent polyposis.
Ulcerative lesions of the mucous membranes of the stomach and duodenum .
Gastrointestinal bleeding in the active phase.
Cerebrovascular bleeding.
Blood clotting disorder.
Inflammatory bowel diseases ( ulcerative colitis, Crohn's disease ) in the acute phase.
Heart failure in the stage of decompensation.
Severe damage to the liver and kidneys.
Arterial hypertension.
Postoperative period of coronary artery bypass grafting.
Lactose intolerance , deficiency , glucose-galactose malabsorption .
Pregnancy and lactation .
Age less than 18 years.

Use with caution when:

hyperbilirubinemia;
coronary heart disease;
chronic heart failure;
cerebrovascular diseases;
diabetes mellitus;
lesions of peripheral arteries;
chronic renal failure;
in old age.

Side effects

From the digestive system: nausea, dyspepsia , diarrhea , vomiting, constipation, peptic ulcer.
From the genitourinary system: urinary tract infections.
From the side of vision and hearing: visual impairment, tinnitus.
From the respiratory system: bronchospasm , rhinitis , shortness of breath, laryngeal edema.
From the nervous system: dizziness , drowsiness , depression .
From the circulatory system: increased pressure.
From the hematopoietic system: anemia, thrombocytopenia, leukopenia.
Skin: rash, purpura , dermatitis , urticaria , Lyell's syndrome.
Allergic reactions: anaphylactoid reactions.

Indications for use

osteoarthritis;
rheumatoid arthritis;
ankylosing spondylitis;
bursitis;
articular syndrome due to gout;
tenosynovitis;
arthralgia;
pain syndrome;
myalgia;
migraine;
neuralgia;
headache and toothache;
algodismenorrhea;
pain from burns and injuries.

Interaction

The drug reduces the effectiveness of antihypertensives, uricosurics and diuretics .

Nizilat enhances the effect of antiplatelet agents, fibrinolytics, anticoagulants , side effects of estrogens, mineralocorticoids.

Cholestyramine and antacids reduce the absorption of Nisylat.

Myelotoxic drugs enhance the hematotoxic properties of the drug.

Naisilate (600mg)

INSTRUCTIONS for the use of the medicinal product for medical use NAYSILAT

Registration number: LP-001588 Trade name of the drug: Naysylat International nonproprietary name of the drug: amtolmetin guacil. Dosage form: film-coated tablets. Composition Each film-coated tablet contains: Active substance: amtolmetin guacil 600 mg; Excipients: lactose monohydrate 40.1 mg, hypromellose (15 cps) 6.0 mg, lactose monohydrate (Flowlac 100) 120.3 mg, colloidal silicon dioxide 1.6 mg, sodium carboxymethyl starch (type-A) 24.0 mg , magnesium stearate 8.0 mg; Film coating: hypromellose (5 pps) 12.5 mg, titanium dioxide 6.25 mg, macrogol-400 1.25 mg. Description Capsule-shaped tablets, film-coated, white to almost white in color, with a characteristic odor. Pharmacotherapeutic group: non-steroidal anti-inflammatory drug. ATC code: M01AB Pharmacological properties Pharmacodynamics Amtolmetin guacil is a non-steroidal anti-inflammatory drug (NSAID), a non-selective cyclooxygenase (COX) inhibitor. Amtolmetin guacil is a precursor to tolmetin. It has anti-inflammatory, analgesic, antipyretic, desensitizing effects, and has a gastroprotective effect. Suppresses pro-inflammatory factors, reduces platelet aggregation; inhibits COX-1 and COX-2, disrupts the metabolism of arachidonic acid, reduces the formation of prostaglandins (including at the site of inflammation), suppresses the exudative and proliferative phases of inflammation. Reduces capillary permeability; stabilizes lysosomal membranes; inhibits the synthesis or inactivates inflammatory mediators (prostaglandins, histamine, bradykinins, cytokines, complement factors). Blocks the interaction of bradykinin with tissue receptors, restores impaired microcirculation and reduces pain sensitivity at the site of inflammation. Affects the thalamic centers of pain sensitivity; reduces the concentration of biogenic amines with algogenic properties; increases the pain sensitivity threshold of the receptor apparatus. Eliminates or reduces the intensity of pain, reduces morning stiffness and swelling, increases the range of motion in the affected joints after 4 days of treatment. The protective effect of amtolmetin guacil on the gastric mucosa is realized by stimulating capsaicin receptors (also called vanilloid receptors) present in the walls of the gastrointestinal tract. Due to the presence of a vanillin group in amtolmetin guacil, it can stimulate capsaitin receptors, which in turn causes the release of calcitonin gene-encoded peptide (CAGP) and a subsequent increase in nitric oxide (NO) production. Both of these actions counterbalance the negative effect caused by the decrease in prostaglandins due to COX inhibition. Amtolmetin guacil was well tolerated by patients with long-term use (for 6 months). Pharmacokinetics Absorption of amtolmetin guacil after oral administration is rapid and complete. The drug is mainly concentrated in the walls of the stomach and intestines, where its very high concentration is maintained for 2 hours after administration. After absorption, amtolmetin guacil is immediately hydrolyzed by plasma esterases to form three metabolites: MED-5, tolmetin and guacol, which are transformed to the active metabolite tolmetin, which penetrates the tissues, exerting a pharmacological effect. The main metabolic pathway of tolmetin is the oxidation of the methyl group on the benzene ring into a carboxyl group. Time to reach maximum concentration (TCmax) after oral administration is 20-60 minutes. Communication with plasma proteins – 99%. The half-life (T1/2) in adults is about 5 hours. Within 24 hours, the drug is almost completely eliminated from the body in the form of glucuronides (with urine - 80%, with bile - 20%). Indications for use: Rheumatoid arthritis, osteoarthritis, ankylosing spondylitis, articular syndrome with exacerbation of gout, bursitis, tenosynovitis. Pain syndrome (weak and moderate intensity): arthralgia, myalgia, neuralgia, migraine, toothache and headache, algomenorrhea; pain from injuries, burns. Intended for symptomatic therapy, reducing pain and inflammation at the time of use, does not affect the progression of the disease. Contraindications for use Hypersensitivity to amtolmetin, tolmetin; complete or incomplete combination of bronchial asthma, recurrent polyposis of the nose or paranasal sinuses and intolerance to acetylsalicylic acid and other NSAIDs (including a history); erosive and ulcerative changes in the mucous membrane of the stomach and duodenum, active gastrointestinal bleeding; cerebrovascular or other bleeding; inflammatory bowel diseases (Crohn's disease, ulcerative colitis) in the acute phase; hemophilia and other bleeding disorders; decompensated heart failure; liver failure or active liver disease; severe renal failure (creatinine clearance less than 30 ml/min), progressive kidney disease, confirmed hyperkalemia; period after coronary artery bypass surgery; arterial hypertension; congenital lactase deficiency, lactose intolerance, glucose-galactose malabsorption; deficiency of glucose-6-phosphate dehydrogenase; pregnancy, lactation period, children under 18 years of age. Precautions for use Hyperbilirubinemia, chronic heart failure, coronary heart disease, cerebrovascular diseases, dyslipidemia / hyperlipidemia, diabetes mellitus, peripheral arterial disease, smoking, chronic renal failure (creatinine clearance 30-60 ml/min), ulcerative lesions of the gastrointestinal tract history, presence of H. pulori infection, long-term use of NSAIDs, alcoholism, severe somatic diseases, old age, simultaneous use of oral glucocorticosteroids (including prednisolone), anticoagulants (including warfarin), antiplatelet agents (including acetylsalicylic acid, clopidogrel ), selective serotonin reuptake inhibitors (including citalopram, fluoxetine, paroxetine, sertraline).

Method of administration and dosage The recommended dose of amtolmetin guacil is 600 mg twice a day. Depending on the degree of control of the symptoms of the disease, the maintenance dose may be reduced to 600 mg once daily. The maximum daily dose is 1800 mg. To maintain the gastroprotective effect of the drug, Naysylat should be taken on an empty stomach. Possible side effects when using the drug The frequency of side effects is classified depending on the frequency of occurrence of the case: often (1-10%), infrequently (0.1-1%), rarely (0.01-0.1%), very rarely (less than 0.01%), including individual messages. From the digestive system: often – nausea; uncommon – dyspepsia, discomfort in the stomach and intestines, bloating; rarely – abdominal pain, diarrhea, vomiting, constipation, gastritis; very rarely - peptic ulcer, liver dysfunction. From the urinary system: increased urea nitrogen in the blood, urinary tract infections From the senses: rarely - tinnitus, visual impairment. From the respiratory system: rarely - bronchospasm, shortness of breath, rhinitis, laryngeal edema. From the central nervous system: often – dizziness, headache, drowsiness; rarely – depression. From the cardiovascular system: often - increased blood pressure. From the hematopoietic organs: rarely - anemia, thrombocytopenia, agranulocytosis, leukopenia. From the skin: uncommon – skin rash (including maculopapular rash), purpura, rare – exfoliative dermatitis (fever with or without chills, redness, thickening or peeling of the skin, swelling and/or tenderness of the tonsils), urticaria, Stevens-Johnson syndrome , Lyell's syndrome. Allergic reactions: rarely - anaphylaxis or anaphylactoid reactions (change in facial skin color, skin rash, urticaria, itching of the skin, tachypnea or dyspnea, swelling of the eyelids, periorbital edema, shortness of breath, difficulty breathing, heaviness in the chest, wheezing). Other: often – weakness; uncommon – swelling (face, legs, ankles, fingers, feet, weight gain); rarely – increased sweating, fever, lymphadenopathy; very rarely - swelling of the tongue. Symptoms of overdose, measures to assist in case of overdose Symptoms: abdominal pain, nausea, vomiting, erosive and ulcerative lesions of the gastrointestinal tract, impaired renal function, metabolic acidosis. Treatment: gastric lavage, administration of adsorbents (activated carbon) and symptomatic therapy (maintaining vital body functions). There is no specific antidote. Interaction with other drugs and (or) foods Inducers of microsomal oxidation in the liver (phenytoin, ethanol, barbiturates, rifampicin, phenylbutazone, tricyclic antidepressants) increase the production of hydroxylated active metabolites. Reduces the effectiveness of uricosuric, antihypertensive drugs and diuretics. Enhances the hypoglycemic effect of sulfonylurea derivatives, the effect of anticoagulants, antiplatelet agents, fibrinolytics, side effects of estrogens, glucocorticosteroids and mineralcorticoids. Antacids and cholestyramine reduce absorption. Increases the concentration of lithium and methotrexate in the blood. In some patients with impaired renal function, co-administration of NSAIDs and angiotensin-converting enzyme (ACE) inhibitors may result in further deterioration of renal function. Myelotoxic drugs increase the manifestations of hematotoxicity of the drug. Special instructions During treatment, it is necessary to monitor the peripheral blood picture and the functional state of the liver and kidneys. Treatment should be stopped 48 hours before determination of 17-ketosteroids. During treatment, you should refrain from engaging in potentially hazardous activities that require increased attention and speed of mental and motor reactions. Release form: Film-coated tablets, 600 mg. 10 tablets per blister made of opaque PVC/PVDC film/aluminum foil. 2 blisters along with instructions for use in a cardboard pack. Storage conditions: In a dry place, protected from light, at a temperature not exceeding 25 °C. Keep out of the reach of children! Shelf life: 2 years. Do not use after the expiration date stated on the packaging. Conditions for dispensing from pharmacies By prescription. Manufacturer Dr. Reddy's Laboratories Ltd. Hyderabad, Andhra Pradesh, India. Address of the place of production Plots 42, 45 and 46, Bachupally Village, Qutbullapur Mandal, Ranga Reddy District, Andhra Pradesh, India.

Send consumer complaints to the following address: Representative office of Dr. Reddy's Laboratories Ltd.: 115035, Moscow, Ovchinnikovskaya embankment, 20, building 1 tel. 783-29-01 fax

Analogues of Nizilat

Level 4 ATC code matches:
Voltaren

Rapten

Zerodol

Dickloberl Retard

Dikloberl N 75

Dicloberl

Ketanov

Dolak

Panoxen

Ketorolac

Naklofen Duo

Naklofen

Olfen-100

Olfen-75

Neurodiclovit

Fanigan

Aertal

Methindol retard

Ortofen

The drug was synthesized relatively recently - analogues of Nizilat are not yet produced. Vimovo (a combination of an NSAID and a proton pump inhibitor) is most similar in action to Nisylate.

Nizilat price

In Russia, the price of Naysilat in standard packaging reaches 380 rubles; in Ukraine, the average price of Naysilat 600 mg No. 20 is 63 hryvnia.

Online pharmacies in RussiaRussia
Online pharmacies in UkraineUkraine
Online pharmacies in KazakhstanKazakhstan

ZdravCity

Nisylat tablets p.p.o.
600mg 20 pcs.Dr. Reddy's lab. RUR 589 order

Pharmacy Dialogue

Nizilat (tablet p/o capt. 600 mg No. 20)Dr. Reddy's
RUR 574 order

Pharmacy24

Naysylate 600 mg No. 10 tablets Dr. Reddy's Laboratories Ltd., India
140 UAH.order

PaniPharmacy

Naysylat tablets Naysylat tablets. 600 mg No. 10 India, Dr. Reddy's
155 UAH order